TY - CHAP
T1 - Delivery of Drug Payloads to Organs and Organ-Systems
AU - Pang, Siew Wai
AU - Soon, Michiele Lee Kiun
AU - Shameli, Kamyar
AU - Janarthanan, Pushpamalar
AU - Teow, Sin Yeang
N1 - Publisher Copyright:
© 2021, Springer Nature Switzerland AG.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/1/22
Y1 - 2021/1/22
N2 - The advancement of nanotechnology has boosted the development of new and modified medicine in treating various human diseases and disorders, particularly in cardiovascular diseases and cancers, which are the two main death-causing killers globally. Nanomaterials are defined as a material with sizes of 1 and 100 nm. Owing to the diverse properties and types of nanomaterials, there is a huge potential utilising them to modify and improve the current drugs and therapeutic strategies. These include enhancing drug effectiveness, increasing target specificity, improving drug stability and bioavailability, increasing body absorption, and minimising off-target cytotoxicity. To achieve the abovementioned drug activities, the responses of the targeted cells, tissues, organ and subsequently the organ system play important parts. Unquestionably, the drug responses could also largely be affected by the pathophysiology and surrounding micro-environments of the diseased models or organs. Vice versa, the drug payloads may also contribute to the alterations in the routine biological processes of the organs or may render toxicity to the target organ or organ systems. This chapter aims to discuss the current nano-systems used for drug delivery and target specificity as well as to provide insights to improve the drug selectivity, safety profile and therapeutic efficacies. The overview of this chapter is depicted in Fig. 11.1.
AB - The advancement of nanotechnology has boosted the development of new and modified medicine in treating various human diseases and disorders, particularly in cardiovascular diseases and cancers, which are the two main death-causing killers globally. Nanomaterials are defined as a material with sizes of 1 and 100 nm. Owing to the diverse properties and types of nanomaterials, there is a huge potential utilising them to modify and improve the current drugs and therapeutic strategies. These include enhancing drug effectiveness, increasing target specificity, improving drug stability and bioavailability, increasing body absorption, and minimising off-target cytotoxicity. To achieve the abovementioned drug activities, the responses of the targeted cells, tissues, organ and subsequently the organ system play important parts. Unquestionably, the drug responses could also largely be affected by the pathophysiology and surrounding micro-environments of the diseased models or organs. Vice versa, the drug payloads may also contribute to the alterations in the routine biological processes of the organs or may render toxicity to the target organ or organ systems. This chapter aims to discuss the current nano-systems used for drug delivery and target specificity as well as to provide insights to improve the drug selectivity, safety profile and therapeutic efficacies. The overview of this chapter is depicted in Fig. 11.1.
UR - http://www.scopus.com/inward/record.url?scp=85102136884&partnerID=8YFLogxK
U2 - 10.1007/978-3-030-61021-0_11
DO - 10.1007/978-3-030-61021-0_11
M3 - Chapter (Book)
AN - SCOPUS:85102136884
SN - 9783030610203
T3 - Nanotechnology in the Life Sciences
SP - 199
EP - 224
BT - Nanotechnology in Medicine
A2 - Arivarasan, Vishnu Kirthi
A2 - Loganathan, Karthik
A2 - Janarthanan, Pushpamalar
PB - Springer
CY - Cham Switzerland
ER -